b细胞编辑:一种新兴的精确肿瘤治疗方法。

3区 医学 Q2 Medicine
Advances in Immunology Pub Date : 2025-01-01 Epub Date: 2024-10-30 DOI:10.1016/bs.ai.2024.10.002
Pritha Roy Choudhury, Mohona Chakravarti, Saptak Banerjee, Rathindranath Baral, Anamika Bose
{"title":"b细胞编辑:一种新兴的精确肿瘤治疗方法。","authors":"Pritha Roy Choudhury, Mohona Chakravarti, Saptak Banerjee, Rathindranath Baral, Anamika Bose","doi":"10.1016/bs.ai.2024.10.002","DOIUrl":null,"url":null,"abstract":"<p><p>Lately, the urgency of precision medicine in cancer care through immunotherapy has reformed the arena of oncology. Although immunomodulatory therapeutics in cancer have been preliminarily concentrated on T-cells, emerging evidences have suggested that intra-tumoral B-cells and plasma cells have significant contributions in cancer prognosis primarily through the production of antibodies. B-cell oriented cancer vaccines have been used in early clinical trials of breast and other cancers after multiple preclinical studies. Passive immunotherapy via administration of monoclonal antibodies (mAbs) and emergence of anti-idiotypic antibodies have led to considerable advancement in oncotherapy. Endogenous production of mAbs would be of significant benefit in recurrent or residual malignancies and permanent infusion would help in the overcoming of issues related to pharmacodynamic variations observed in case of intravenous inoculations of bi or tri specific mAbs. This has directed towards the development of genome reprogrammed B-cells with the capability of yielding therapeutic mAbs independently. Genetic alteration through clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) nucleases have enabled the introduction of transgenes into B-cell genome thereby stimulating the plasma cells to produce exogenous remedial antibodies. It also facilitates ex vivo B-cell editing to elevate specificities of antigen receptors and generate target specific antibody responses which cannot normally be evoked in patient's immune system. Hence, genome-altered B-cells possess the potential of engineered therapeutics against certain malignancies. Co-operation of B-cells in T-cell based vaccines are ultimate need for vaccine success. In this chapter, the mechanisms, challenges and potential advantages of B-cell editing in cancer immune therapy shall be explored. The prospects of B-cell editing in onco-therapy will be clearly elucidated with all its strength and weaknesses.</p>","PeriodicalId":50862,"journal":{"name":"Advances in Immunology","volume":"166 ","pages":"103-135"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"B-cell editing: An emerging alternative of precision oncotherapy.\",\"authors\":\"Pritha Roy Choudhury, Mohona Chakravarti, Saptak Banerjee, Rathindranath Baral, Anamika Bose\",\"doi\":\"10.1016/bs.ai.2024.10.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Lately, the urgency of precision medicine in cancer care through immunotherapy has reformed the arena of oncology. Although immunomodulatory therapeutics in cancer have been preliminarily concentrated on T-cells, emerging evidences have suggested that intra-tumoral B-cells and plasma cells have significant contributions in cancer prognosis primarily through the production of antibodies. B-cell oriented cancer vaccines have been used in early clinical trials of breast and other cancers after multiple preclinical studies. Passive immunotherapy via administration of monoclonal antibodies (mAbs) and emergence of anti-idiotypic antibodies have led to considerable advancement in oncotherapy. Endogenous production of mAbs would be of significant benefit in recurrent or residual malignancies and permanent infusion would help in the overcoming of issues related to pharmacodynamic variations observed in case of intravenous inoculations of bi or tri specific mAbs. This has directed towards the development of genome reprogrammed B-cells with the capability of yielding therapeutic mAbs independently. Genetic alteration through clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) nucleases have enabled the introduction of transgenes into B-cell genome thereby stimulating the plasma cells to produce exogenous remedial antibodies. It also facilitates ex vivo B-cell editing to elevate specificities of antigen receptors and generate target specific antibody responses which cannot normally be evoked in patient's immune system. Hence, genome-altered B-cells possess the potential of engineered therapeutics against certain malignancies. Co-operation of B-cells in T-cell based vaccines are ultimate need for vaccine success. In this chapter, the mechanisms, challenges and potential advantages of B-cell editing in cancer immune therapy shall be explored. The prospects of B-cell editing in onco-therapy will be clearly elucidated with all its strength and weaknesses.</p>\",\"PeriodicalId\":50862,\"journal\":{\"name\":\"Advances in Immunology\",\"volume\":\"166 \",\"pages\":\"103-135\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.ai.2024.10.002\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.ai.2024.10.002","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

最近,通过免疫疗法治疗癌症的精准医学的紧迫性已经改变了肿瘤学领域。虽然癌症的免疫调节疗法初步集中在t细胞上,但新出现的证据表明,肿瘤内的b细胞和浆细胞主要通过产生抗体对癌症预后有重要贡献。经过多次临床前研究,b细胞导向的癌症疫苗已用于乳腺癌和其他癌症的早期临床试验。通过单克隆抗体(mab)的被动免疫治疗和抗独特型抗体的出现导致了肿瘤治疗的长足进步。内源性单克隆抗体的产生将对复发或残留的恶性肿瘤有显著的好处,永久输注将有助于克服静脉注射双或三特异性单克隆抗体时观察到的药效学变化问题。这直接导致了基因组重编程b细胞的发展,具有独立产生治疗性单克隆抗体的能力。通过聚集规律间隔短回文重复序列(CRISPR)/CRISPR相关蛋白9 (Cas9)核酸酶的遗传改变,可以将转基因引入b细胞基因组,从而刺激浆细胞产生外源性补救抗体。它还有助于体外b细胞编辑,以提高抗原受体的特异性,并产生在患者免疫系统中通常无法引起的靶向特异性抗体反应。因此,基因组改变的b细胞具有针对某些恶性肿瘤的工程治疗的潜力。b细胞在t细胞疫苗中的协同作用是疫苗成功的最终需要。本章将探讨b细胞编辑在癌症免疫治疗中的机制、挑战和潜在优势。b细胞编辑在肿瘤联合治疗中的前景将清楚地阐明其所有优势和劣势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
B-cell editing: An emerging alternative of precision oncotherapy.

Lately, the urgency of precision medicine in cancer care through immunotherapy has reformed the arena of oncology. Although immunomodulatory therapeutics in cancer have been preliminarily concentrated on T-cells, emerging evidences have suggested that intra-tumoral B-cells and plasma cells have significant contributions in cancer prognosis primarily through the production of antibodies. B-cell oriented cancer vaccines have been used in early clinical trials of breast and other cancers after multiple preclinical studies. Passive immunotherapy via administration of monoclonal antibodies (mAbs) and emergence of anti-idiotypic antibodies have led to considerable advancement in oncotherapy. Endogenous production of mAbs would be of significant benefit in recurrent or residual malignancies and permanent infusion would help in the overcoming of issues related to pharmacodynamic variations observed in case of intravenous inoculations of bi or tri specific mAbs. This has directed towards the development of genome reprogrammed B-cells with the capability of yielding therapeutic mAbs independently. Genetic alteration through clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) nucleases have enabled the introduction of transgenes into B-cell genome thereby stimulating the plasma cells to produce exogenous remedial antibodies. It also facilitates ex vivo B-cell editing to elevate specificities of antigen receptors and generate target specific antibody responses which cannot normally be evoked in patient's immune system. Hence, genome-altered B-cells possess the potential of engineered therapeutics against certain malignancies. Co-operation of B-cells in T-cell based vaccines are ultimate need for vaccine success. In this chapter, the mechanisms, challenges and potential advantages of B-cell editing in cancer immune therapy shall be explored. The prospects of B-cell editing in onco-therapy will be clearly elucidated with all its strength and weaknesses.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in Immunology
Advances in Immunology 医学-免疫学
CiteScore
9.90
自引率
0.00%
发文量
13
期刊介绍: Advances in Immunology has provided students and researchers with the latest information in Immunology for over 50 years. You can continue to rely on Advances in Immunology to provide you with critical reviews that examine subjects of vital importance to the field through summary and evaluation of current knowledge and research. The articles stress fundamental concepts, but also evaluate the experimental approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信